Publicaciones en colaboración con investigadores/as de Karolinska University Hospital (14)

2024

  1. 2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)

    European Heart Journal, Vol. 45, Núm. 36, pp. 3314-3414

2023

  1. Large-scale expansions of Friedreich's ataxia GAA•TTC repeats in an experimental human system: role of DNA replication and prevention by LNA-DNA oligonucleotides and PNA oligomers

    Nucleic Acids Research, Vol. 51, Núm. 16, pp. 8532-8549

2022

  1. Challenges in cardiovascular pharmacogenomics implementation: a viewpoint from the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy

    European heart journal. Cardiovascular pharmacotherapy, Vol. 8, Núm. 1, pp. 100-103

  2. Facing the challenge of polypharmacy when prescribing for older people with cardiovascular disease. A review by the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy

    European heart journal. Cardiovascular pharmacotherapy, Vol. 8, Núm. 4, pp. 406-419

  3. Potentially inappropriate prescriptions in heart failure with reduced ejection fraction: ESC position statement on heart failure with reduced ejection fraction-specific inappropriate prescribing

    European heart journal. Cardiovascular pharmacotherapy, Vol. 8, Núm. 2, pp. 187-210

  4. Subgroup analyses in randomized clinical trials: value and limitations. Review #3 on important aspects of randomized clinical trials in cardiovascular pharmacotherapy

    European Heart Journal - Cardiovascular Pharmacotherapy, Vol. 8, Núm. 3, pp. 302-310

  5. The role of pharmacogenomics in contemporary cardiovascular therapy: a position statement from the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy

    European heart journal. Cardiovascular pharmacotherapy, Vol. 8, Núm. 1, pp. 85-99

2021

  1. The age of randomized clinical trials: Three important aspects of randomized clinical trials in cardiovascular pharmacotherapy with examples from lipid, diabetes, and antithrombotic trials

    European Heart Journal - Cardiovascular Pharmacotherapy, Vol. 7, Núm. 5, pp. 453-459

2020

  1. Lipid management in rheumatoid arthritis: A position paper of the Working Group on Cardiovascular Pharmacotherapy of the European Society of Cardiology

    European Heart Journal - Cardiovascular Pharmacotherapy, Vol. 6, Núm. 2, pp. 104-114

2019

  1. Oral anticoagulation in patients with non-valvular atrial fibrillation and a CHA2DS2-VASc score of 1: A current opinion of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy and European Society of Cardiology Council on Stroke

    European Heart Journal - Cardiovascular Pharmacotherapy, Vol. 5, Núm. 3, pp. 171-180

2018

  1. Expert consensus document on the management of hyperkalaemia in patients with cardiovascular disease treated with renin angiotensin aldosterone system inhibitors: Coordinated by the Working Group on Cardiovascular Pharmacotherapy of the European Society of Cardiology

    European Heart Journal - Cardiovascular Pharmacotherapy, Vol. 4, Núm. 3, pp. 180-188

  2. Reasons for disparity in statin adherence rates between clinical trials and real-world observations: A review

    European Heart Journal - Cardiovascular Pharmacotherapy, Vol. 4, Núm. 4, pp. 230-236

2017

  1. Gender differences in the effects of cardiovascular drugs

    European Heart Journal - Cardiovascular Pharmacotherapy, Vol. 3, Núm. 3, pp. 163-182

2007

  1. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: Full text

    Diabetes, Stoffwechsel und Herz, Vol. 16, Núm. 7